Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robotic surgery showdown: single port vs. multi port for prostate cancer

NCT ID NCT07666217

Knowledge-focused Sponsor: Intuitive Surgical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather information, not to test a new drug or treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 625 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with localized prostate cancer who underwent robot assisted radical prostatectomy using either the da Vinci SP extraperitoneal approach or the robotic multi port transperitoneal approach at participating institutions in Japan.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with localized prostate cancer (clinical stage T1-T3a, N0, M0) eligible for radical prostatectomy 2. Patients who underwent RARP via SP-EA or MP-TA on or after January 1, 2023 3. Patients with available postoperative follow-up data for ≥6 months (≥166 days) \*note 1) Exclusion Criteria: 1. Patients who have expressed an intention to refuse the use of their data for this study 2. Patients who underwent RARP using surgical approaches other than those specified in the inclusion criteria (e.g., transvesical approach) 3. Patients who underwent RARP with pelvic lymph node dissection (PLND) 4. Patients with a history of radiotherapy for prostate cancer 5. Any other patients whom the principal investigator or a co-investigator deem inappropriate, such as those with missing outcome data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Ageo Central General Hospital

    Ageo, Saitama, 362-8588, Japan

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, 470-1192, Japan

  • Ichinomiyanishi Hospital

    Ichinomiya, Aichi-ken, 494-0001, Japan

  • Kyoto City Hospital

    Kyoto, Kyoto, 604-8845, Japan

  • Mie University Hospital

    Tsu, Mie-ken, 514-8507, Japan

  • National Cancer Center Hospital

    Tokyo, Tokyo, 104-0045, Japan

  • Saiseikai Yokohamashi Tobu Hospital

    Yokohama, Kanagawa, 230-0012, Japan

  • Tokyo Medical Center

    Tokyo, Tokyo, 152-8902, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.